AKCİĞER KANSERİNDE TÜMÖR BOYUTU SERUM LDH DÜZEYİNİ ETKİLER Mİ?
Son zamanlarda yapılan pek çok çalışmada, serum Laktat Dehidrogenaz (LDH) düzeyinin prognozu kötü ve ileri evre akciğer kanserinde yüksek bulunduğu ve prognostik faktör yönünden kullanılabileceği bildirilmiştir. Bizim çalışmamızın amacı akciğer kanserli olgularda serum LDH düzeyi ile tümörün boyutları ve evresi arasında korelasyonu belirlemekti. ‚alışmaya histopatolojik olarak akciğer kanseri tanısı konan 110 olgu alındı. Tedavi öncesi serum LDH düzeyi, tümörün boyutları, TNM evresi belirlendi. İstatistiksel olarak LDH düzeyi ile tümörün boyutu ve evresi arasında anlamlı korelasyon saptanmadı. Tümörün hacmi ile hastalığın prognozu yönünde yapılacak ileri çalışmalara gereksinim olduğunu düşünüyoruz.
DOES TUMOUR DIMENSION AFFECT SERUM LDH LEVEL IN LUNG CANCER?
Currently studies showed that serum lactat dehydrogenase (LDH) levels was increased in patients with poor prognose and it could use as a prognostic factor in advanced lung cancer. In our study we aimed to examine the serum LDH level in 110 cases with lung cancer and to define the relationship between tumour dimension and stage. In our study statistically we revealed that serum LDH levels didn't differ according to tumour dimension and stage. We think that further controlled studies that will use survival and tumour volume are necessary.
___
- 1. Halilçolar H, Tatar D, Ertu¤rul G ve ark.
Epidemiyoloji. In: Akci¤er kanseri. Akkoçlu
A, Öztürk C (Ed). Toraks Kitaplar› Ankara
1999: 17-21.
- 2. Göksel T, Savafl R, Soyer S. Evreleme In:
Akci¤er kanseri. Akkoçlu A, Öztürk C (Ed).
Toraks Kitaplar› Ankara 1999: 44-7.
- 3. Tafl F, Ayd›ner A, Demir C, Topuz E. Serum
lactate dehydrogenase levels at presentation
predict outcome of patients with limited
stage small cell lung cancer. Am J Clin
Oncol (CCT) 2001; 24(4): 376-8.
- 4. Goldman RD, Kaplan NO, Hall TC. Lactic
dehydrogenase in human neoplastic tissues.
Cancer Res 1964; 24: 389-99.
- 5. Osterlind K, Hansen HH, Hansen M, et al.
Long-term disease-free survival in small cell
carcinoma of the lung: a study of clinical
determinants. J Clin Oncol 1986; 4: 1307-13.
- 6. Cerny T, Blair V, Anderson H, et al. Pretreatment
prognostic factors and scoring
system in 407 small cell lung cancer patients.
Int J Cancer 1987; 39: 146-9.
- 7. Cohen MH, Makuch R, Johnston-Early A, et
al. Laboratory parameters as an alternative
to performance status in prognostic stratification
of patients with small cell lung
cancer. Cancer Treat Rep 1981; 65: 187-95.
- 8. Feld R, De Boer G, Evans WK. Prognostic
factors in patients with small cell carcinoma
of the lung. Proc Am Assoc Cancer Res
1983; 24: 575.
- 9. Osterlind K, Ihde DC, Ettinger DS, et al.
Staging and prognostic factors in small cell
lung carcinoma of the lung. Cancer Treat
Rep 1983; 97: 3-9.
- 10. Bremnes RM, Sundstrom S, Aasebo U, et al.
The value of prognostic factors in small cell
lung cancer: results from a randomised multicenter
study with minimum 5 year follow up.
Lung Cancer 2003; 39(3): 303-13.
- 11. Koukourakis MI, Giatromanolaki A, Sivridis E,
et al. Lactate dehydrogenase-5 (LDH-5) overexprssion
in nonsmall cell lung cancer tissue
is linked to tumour hypoxia, angiogenic
factor production and poor prognosis. Br J
Cancer 2003; 89(5): 877-85.
- 12. Stokkel MP, Van Eck-Smith BL, Zwindermann
AH et al. The diagnostic value of pretreatment
serum LDH in patients with limited disease
small cell lung carcinoma. Int J Biol Markers
1997;12(4): 162-7.
- 13. Brundage MD, Davies D, Mackillop WJ. Prognostic
Factors in Non-small Cell Lung Cancer:
A Decade of Progress. Chest 2002; 122:
1037-57.
- 14. Albain KS, Crowley JJ, LeBlanc M, et al. Survival
determinants in extensive-stage non-small-cell
lung cancer: the Southwest Oncology Group
experience. J Clin Oncol 1991; 9: 1618-26.
- 15. Wigren T, Oksanen H, Kellokumpu-Lehtinen
PA. Practical prognostic index for inoperable
non-small-cell lung cancer. J Cancer Res Clin
Oncol 1997; 123: 259-66.
- 16. Nonaka M, Kadokura M, Yamamoto S, et al.
Tumor dimension and prognosis in surgically
treated lung cancer: for intentional limited
resection. Am J Clin Oncol 2003; 26(5): 499-503.
- 17. Cibas ES, Melamed MR, Zaman MB, et al.
The effect of tumor size and tumor cell DNA
content on the survival of patients with
stage I adenocarcinoma of the lung. Cancer
1989; 63: 1552-6.